Endogenous carbon monoxide suppression stimulates bile acid-dependent biliary transport in perfused rat liver. 1997

T Sano, and M Shiomi, and Y Wakabayashi, and Y Shinoda, and N Goda, and T Yamaguchi, and Y Nimura, and Y Ishimura, and M Suematsu
Department of Biochemistry, School of Medicine, Keio University, Tokyo, Japan.

This study aimed to investigate whether carbon monoxide (CO), a product of heme oxygenase that degrades protoheme IX, serves as an endogenous modulator for biliary transport. To that end, effects of zinc protoporphyrin IX (ZnPP), a heme oxygenase inhibitor, on the biliary transport were tested in perfused rat liver. Perfusion of 1 microM ZnPP abolished detectable levels of CO in the venous perfusate and increased bile acid-dependent bile output accompanying an increased secretion of bile salts. The ZnPP-induced choleresis coincided with a reduction of tissue guanosine 3',5'-cyclic monophosphate (cGMP) levels and a decrease in vascular conductance. On administration of 2.5 microM CO, ZnPP-elicited choleresis, decreases in vascular conductance, and cGMP levels were all attenuated. Treatment with 1 microM 8-bromoguanosine 3',5'-cyclic monophosphate (8-BrcGMP) partly attenuated the ZnPP-induced choleresis in concert with repression of vascular conductance. Furthermore, treatment of the liver with methylene blue, a guanylate cyclase inhibitor, evoked a choleresis similar to that induced by ZnPP. Thus endogenous CO suppression stimulates the biliary transport in part through a cGMP-dependent mechanism.

UI MeSH Term Description Entries
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008297 Male Males
D009569 Nitric Oxide A free radical gas produced endogenously by a variety of mammalian cells, synthesized from ARGININE by NITRIC OXIDE SYNTHASE. Nitric oxide is one of the ENDOTHELIUM-DEPENDENT RELAXING FACTORS released by the vascular endothelium and mediates VASODILATION. It also inhibits platelet aggregation, induces disaggregation of aggregated platelets, and inhibits platelet adhesion to the vascular endothelium. Nitric oxide activates cytosolic GUANYLATE CYCLASE and thus elevates intracellular levels of CYCLIC GMP. Endogenous Nitrate Vasodilator,Mononitrogen Monoxide,Nitric Oxide, Endothelium-Derived,Nitrogen Monoxide,Endothelium-Derived Nitric Oxide,Monoxide, Mononitrogen,Monoxide, Nitrogen,Nitrate Vasodilator, Endogenous,Nitric Oxide, Endothelium Derived,Oxide, Nitric,Vasodilator, Endogenous Nitrate
D009599 Nitroprusside A powerful vasodilator used in emergencies to lower blood pressure or to improve cardiac function. It is also an indicator for free sulfhydryl groups in proteins. Nitroferricyanide,Sodium Nitroprusside,Cyanonitrosylferrate,Ketostix,Naniprus,Nipride,Nipruton,Nitriate,Nitropress,Nitroprussiat Fides,Nitroprusside, Disodium Salt,Nitroprusside, Disodium Salt, Dihydrate,Disodium Salt Nitroprusside,Nitroprusside, Sodium
D010101 Oxygen Consumption The rate at which oxygen is used by a tissue; microliters of oxygen STPD used per milligram of tissue per hour; the rate at which oxygen enters the blood from alveolar gas, equal in the steady state to the consumption of oxygen by tissue metabolism throughout the body. (Stedman, 25th ed, p346) Consumption, Oxygen,Consumptions, Oxygen,Oxygen Consumptions
D010477 Perfusion Treatment process involving the injection of fluid into an organ or tissue. Perfusions
D011524 Protoporphyrins Porphyrins with four methyl, two vinyl, and two propionic acid side chains attached to the pyrrole rings. Protoporphyrin IX occurs in hemoglobin, myoglobin, and most of the cytochromes.
D002248 Carbon Monoxide Carbon monoxide (CO). A poisonous colorless, odorless, tasteless gas. It combines with hemoglobin to form carboxyhemoglobin, which has no oxygen carrying capacity. The resultant oxygen deprivation causes headache, dizziness, decreased pulse and respiratory rates, unconsciousness, and death. (From Merck Index, 11th ed) Monoxide, Carbon
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D006152 Cyclic GMP Guanosine cyclic 3',5'-(hydrogen phosphate). A guanine nucleotide containing one phosphate group which is esterified to the sugar moiety in both the 3'- and 5'-positions. It is a cellular regulatory agent and has been described as a second messenger. Its levels increase in response to a variety of hormones, including acetylcholine, insulin, and oxytocin and it has been found to activate specific protein kinases. (From Merck Index, 11th ed) Guanosine Cyclic 3',5'-Monophosphate,Guanosine Cyclic 3,5 Monophosphate,Guanosine Cyclic Monophosphate,Guanosine Cyclic-3',5'-Monophosphate,3',5'-Monophosphate, Guanosine Cyclic,Cyclic 3',5'-Monophosphate, Guanosine,Cyclic Monophosphate, Guanosine,Cyclic-3',5'-Monophosphate, Guanosine,GMP, Cyclic,Guanosine Cyclic 3',5' Monophosphate,Monophosphate, Guanosine Cyclic

Related Publications

T Sano, and M Shiomi, and Y Wakabayashi, and Y Shinoda, and N Goda, and T Yamaguchi, and Y Nimura, and Y Ishimura, and M Suematsu
August 2003, Antioxidants & redox signaling,
T Sano, and M Shiomi, and Y Wakabayashi, and Y Shinoda, and N Goda, and T Yamaguchi, and Y Nimura, and Y Ishimura, and M Suematsu
February 1994, The American journal of physiology,
T Sano, and M Shiomi, and Y Wakabayashi, and Y Shinoda, and N Goda, and T Yamaguchi, and Y Nimura, and Y Ishimura, and M Suematsu
November 1995, The Journal of clinical investigation,
T Sano, and M Shiomi, and Y Wakabayashi, and Y Shinoda, and N Goda, and T Yamaguchi, and Y Nimura, and Y Ishimura, and M Suematsu
September 1999, The American journal of physiology,
T Sano, and M Shiomi, and Y Wakabayashi, and Y Shinoda, and N Goda, and T Yamaguchi, and Y Nimura, and Y Ishimura, and M Suematsu
May 1992, The American journal of physiology,
T Sano, and M Shiomi, and Y Wakabayashi, and Y Shinoda, and N Goda, and T Yamaguchi, and Y Nimura, and Y Ishimura, and M Suematsu
July 1999, Hepatology (Baltimore, Md.),
T Sano, and M Shiomi, and Y Wakabayashi, and Y Shinoda, and N Goda, and T Yamaguchi, and Y Nimura, and Y Ishimura, and M Suematsu
October 1975, Canadian journal of physiology and pharmacology,
T Sano, and M Shiomi, and Y Wakabayashi, and Y Shinoda, and N Goda, and T Yamaguchi, and Y Nimura, and Y Ishimura, and M Suematsu
November 1990, The American journal of physiology,
T Sano, and M Shiomi, and Y Wakabayashi, and Y Shinoda, and N Goda, and T Yamaguchi, and Y Nimura, and Y Ishimura, and M Suematsu
August 2003, Journal of biochemistry,
T Sano, and M Shiomi, and Y Wakabayashi, and Y Shinoda, and N Goda, and T Yamaguchi, and Y Nimura, and Y Ishimura, and M Suematsu
September 1994, Hepatology (Baltimore, Md.),
Copied contents to your clipboard!